Photochromic compounds
    4.
    发明授权
    Photochromic compounds 有权
    光致变色化合物

    公开(公告)号:US07582749B2

    公开(公告)日:2009-09-01

    申请号:US11925044

    申请日:2007-10-26

    摘要: Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula—[S1]c-[Q1 —[S2]d]d′-[Q2 —[S3]e]e′-[Q3 —[S4]f]f′—S5—P, which is described herein.

    摘要翻译: 本文公开的各种非限制性实施方案通常涉及光致变色化合物,其可以是热可逆的或不可逆的,以及由其制成的制品。 其它非限制性实施方案涉及光致变色二色性化合物,其可以是热可逆的或不可逆的,以及由其制备的制品。 例如,一个非限制性实施方案提供了适于具有至少第一状态和第二状态的热可逆的光致变色化合物,其中所述热可逆的光致变色化合物在至少一种状态中的平均吸收比大于2.3,如所确定的 根据细胞方法 另一个非限制性实施方案提供了一种光致变色化合物,其包含:(a)至少一种选自吡喃,恶嗪和吡啶的光致变色基团; 由式 - [S1] c- [Q1- [S2] d] d' - [Q2- [S3] e] e'表示的至少一个延长剂L连接到至少一个光致变色基团上, - [Q3 - [S4] f] f'-S5-P,这里描述。

    Polarizing, photochromic devices and methods of making the same
    6.
    发明授权
    Polarizing, photochromic devices and methods of making the same 有权
    偏光,光致变色装置及制作方法

    公开(公告)号:US07978391B2

    公开(公告)日:2011-07-12

    申请号:US11590055

    申请日:2006-10-31

    IPC分类号: G02F1/03

    摘要: A liquid crystal cell including a first substrate having a first surface; a second substrate having a second surface, wherein the second surface of the second substrate is opposite and spaced apart from the first surface of the first substrate so as to define a region; and within the region defined by the first surface and the second surface, a liquid crystal material adapted to be at least partially ordered and at least one thermally reversible photochromic-dichroic compound adapted to be at least partially aligned and having an average absorption ratio greater than 2.3 in an activated state.

    摘要翻译: 一种液晶单元,包括具有第一表面的第一基板; 具有第二表面的第二衬底,其中所述第二衬底的所述第二表面与所述第一衬底的所述第一表面相对并间隔开以限定区域; 并且在由第一表面和第二表面限定的区域内,适于至少部分排列的液晶材料和至少一种热可逆光致变色二色性化合物,其适于至少部分对准并且具有大于 2.3处于激活状态。

    Photochromic compounds
    9.
    发明授权
    Photochromic compounds 有权
    光致变色化合物

    公开(公告)号:US07560124B2

    公开(公告)日:2009-07-14

    申请号:US11924925

    申请日:2007-10-26

    摘要: Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula —[S1]c-[Q1-[S2]d]d′-[Q2-[S3]e]e′-[Q3-[S4]f]f′—S5—P, which is described herein.

    摘要翻译: 本文公开的各种非限制性实施方案通常涉及光致变色化合物,其可以是热可逆的或不可逆的,以及由其制成的制品。 其它非限制性实施方案涉及光致变色二色性化合物,其可以是热可逆的或不可逆的,以及由其制备的制品。 例如,一个非限制性实施方案提供了适于具有至少第一状态和第二状态的热可逆的光致变色化合物,其中所述热可逆的光致变色化合物在至少一种状态中的平均吸收比大于2.3,如所确定的 根据细胞方法 另一个非限制性实施方案提供了一种光致变色化合物,其包含:(a)至少一种选自吡喃,恶嗪和吡啶的光致变色基团; 由式 - [S1] c- [Q1- [S2] d] d' - [Q2- [S3] e] e'表示的至少一个延长剂L连接到至少一个光致变色基团上, - [Q3- [S4] f] f'-S5-P,其在本文中描述。